Adherence to Osteoporosis Treatment

Bessette L Ste-Marie LG Jean S The care gap in diagnosis and treatment of women with a fragility fracture. Osteoporos Int 2008; 19 (1): 79–86.

Yeaw J Benner JS Walt JG Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm 2009; 15: 728–40.

Harvey N Dennison E Cooper C . Osteoporosis: impact on health and economics. Nat Rev Rheumatol 2010; 6: 99–105.

Osteoporosis Canada. National report points to unmet needs of Canadians living with osteoporosis. November 24, 2008. Available: www.osteoporosis.ca/index.php/ci_id/7565/la_id/1.htm (accessed March 9, 2011).

Papaioannou A Morin S Cheung AM 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ 2010; 182: 1864–73.

Siris ES Harris ST Rosen CJ Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006; 81: 1013–22.

Kamatari M Koto S Ozawa N Factors affecting long-term compliance of osteoporotic patients with bisphosphonate treatment and QOL assessment in actual practice: alendronate and risedronate. J Bone Miner Metab 2007; 25: 302–9.

Copher R Buzinec P Zarotsky V Physician perception of patient adherence compared to patient adherence of osteoporosis medications from pharmacy claims. Curr Med Res Opin 2010; 26: 777–85.